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Abstract 
Introduction: The fractional exhaled nitric oxide (FENO) is a marker for type 2 
inflammation used in diagnostics and management of asthma. In order to use FENO as a 
reliable biomarker, it is important to investigate factors that influence FENO in healthy 
individuals. Men have higher levels of FENO than women, but it is unclear whether 
determinants of FENO differ by sex. 
  
Objective: To identify determinants of FENO in men and women without lung diseases.  
 
Method: FENO was validly measured in 3,881 healthy subjects that had answered the main 
questionnaire of the European Community Respiratory Health Survey III without airways 
or lung disease 
 
Results: Exhaled NO levels were 21.3% higher in men compared with women p<0.001. 
Being in the upper age quartile (60.3–67.6 years) men had 19.2 ppb (95% CI: 18.3, 20.2) 
higher FENO than subjects in the lowest age quartile (39.7–48.3 years) p=0.02. Women in 
the two highest age quartiles (54.6–60.2 and 60.3–67.6 years) had 15.4 ppb (14.7, 16.2), 
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p=0.03 and 16.4 ppb (15.6, 17.1), p=<0.001 higher FENO, compared with the lowest age 
quartile.  
Height was related to 8% higher FENO level in men (p<0.001) and 5% higher FENO levels 
in women (p=0.008). Men who smoked had 37% lower FENO levels and women had 30% 
lower levels compared with never-smokers (p<0.001 for both). Men and women sensitized 
to both grass and perennial allergens had higher FENO levels compared with non-
sensitized subjects 26% and 29%, p<0.001 for both. 
 
 
Conclusion & Clinical Relevance: FENO levels were higher in men than women. Similar 
effects of current smoking, height, and IgE sensitization were found in both sexes. FENO 
started increasing at lower age in women than in men, suggesting that interpretation of 
FENO levels in adults aged over 50 years should take into account age and sex.  
 






Nitric oxide (NO) serves many functions throughout the body. It is produced by the 
epithelium as part of the immune defence against pathogens, and is involved in 
neurotransmission in the peripheral and central nervous systems, as well as the regulation 
of vascular and bronchiolar tone. 
 
Exhaled NO reflects mainly the respiratory epithelium production of NO, resulting from 
activation of inducible NO synthase (iNOS), which is controlled by signal transducer and 
activator of transcription (STAT)-1 under the influence of homeostatic interferon-γ(1). The 
concentrations are generally low in healthy individuals. However, high concentrations of 
exhaled NO are seen in chronic inflammatory diseases, such as asthma, mainly due to type 
2 inflammation resulting in increased activation of iNOS. Airway infections, especially 
rhinovirus, and allergic rhinitis are also related to higher levels of exhaled NO(2). 
 
The measurement of fractional exhaled NO (FENO) is a useful, non-invasive method to 
assist with diagnosis of asthma and monitor treatment effects. In recent years, FENO has 
been used as a marker for eosinophilic airway inflammation and asthma(3), and to identify 
steroid responsiveness in individuals with chronic respiratory symptoms caused by airway 
inflammation(4).  
 
For FENO to be reliable as a biomarker, it is important to know factors that influence FENO 
values. Currently, it is known that FENO values are influenced by age(5), gender(5, 6), 
height(5), atopy(5, 6), smoking(5, 7), respiratory infections(5), environmental factors(8), 
physical activity(9), and ethnicity(10). Females have consistently been reported to have 
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lower FENO levels than men with about 25% lower levels(5, 6). Some of the explanation 
might reside in differences in height, another known determinant of FENO, but other 
differences appear to be exist with regard to gender. Moreover, the effect of different 
known determinants of FENO has not been studied with regard to gender. Specifically, the 
relation with age appears to be different with regard to gender, as a recent publication 
suggests that after a period in early adulthood with no relation between age and FENO, an 
increase of FENO with age is found at age around 45 in women and 59 years in men(11). 
 
In this study, we aimed to describe determinants of FENO in men and women, with special 
emphasis on gender differences, in subjects without lung disease (asthma, chronic 
obstructive lung function, and emphysema) in the third European Community Respiratory 






This is a cross-sectional analysis based on the third follow-up of ECRHS (ECRHS III), 
performed between the years 2010–2013, using data from 25 centres across 11 European 
countries and Australia.  
 
Briefly, ECRHS is an international multicentre population-based study of asthma and 
allergy, which was first performed in the early 1990s. The subjects, age 20–44 years, were 
first randomly selected to complete a short postal questionnaire about asthma symptoms 
and attacks in the preceding 12 months, current use of asthma medication, and presence of 
nasal allergies including hay fever. Both a random sample and a symptomatic sample of 
responders were invited to attend further examinations at their study centre. Current 
analysis is based on the random population sample. Follow-up studies were performed in 
2000–2002 (ECRHS II) and 2010–2013 (ECRHS III). Further details about ECRHS have 
been published elsewhere(12, 13) and can also be found on the homepage: www.ecrhs.org.  
 
Of 5,483 participants in ECRHS III, 1,004 were excluded due to current asthma and/or 
asthma symptoms in the last 12 months, 83 due to self-reported physician-diagnosed 
chronic obstructive pulmonary disease and emphysema, and 176 due to use of inhaled 
medicines in the last 12 months. Further, 339 subjects with respiratory symptoms at 
ECRHS I (symptomatic sample)(14) were also excluded. Thus, the final study population 
included 3,881 participants, aged 39.7–67.6 years (men: 40.0–67.3 years), who underwent 




Questionnaires and measurements 
Participants had to be free from respiratory infections the 2 weeks preceding the clinical 
examination. An interviewer-led questionnaire contained questions on respiratory 
symptoms, self-reported asthma, chronic obstructive pulmonary disease and emphysema, 
use of inhaled drugs in the last 12 months, allergic disorders, and smoking habits. 
Participants were also asked whether they had any nasal allergies including hay fever.  
 
Current asthma was defined as self-reported asthma with at least one respiratory symptom 
(wheezing, nocturnal tightness in the chest, attacks of shortness of breath following 
strenuous activity, at rest or at night-time) in the last 12 months and/or use of asthma 
medication. Chronic obstructive pulmonary disease (COPD) and emphysema were defined 
by self-reported physician diagnosis, whereas hay fever was defined by self-report of hay 
fever or other allergies with similar symptoms in the last 12 months.  
 
Anthropometry 
Participant height and weight were measured by trained health technicians and used to 
calculate body mass index (BMI) (weight [kg]/height [m2]). BMI was classified in 
accordance with World Health Organization categories: underweight (< 18.5 kg/m2), 
normal weight (18.5–25 kg/m2), overweight (>25–30 kg/m2), obese (>30–35 kg/m2), and 
very obese (≥ 35 kg/m2). 
 
Smoking 
A smoker was defined as someone who had smoked at least 20 packs of cigarettes or 360 
grams of tobacco throughout life, or at least one cigarette a day or one cigar a week for at 
least one year. Based on smoking habits during the month previous to the study, smokers 
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were further divided into current and ex-smokers. Never smokers were defined as subjects 
who never smoked or smoked less than the amount used above to define smokers. 
Additional questions were asked about age of smoking debut, whether they had stopped or 
cut down, and the amount currently/previously smoked. The mean number of cigarettes, 
cigars, cigarillos, and grams of pipe tobacco smoked per day was used to quantify exposure 
in current smokers(15). Lifetime exposure to smoking was calculated in pack-years (1 
pack-year equals smoking 20 cigarettes (1 pack) per day for 1 year). Time since stopped 
smoking was defined as the period of time (in years) since ex-smokers had quit smoking. 
 
Immunoglobulin E (IgE) sensitization and total IgE 
IgE analysis was performed in a single central laboratory (AMC Amsterdam) by using the 
ImmunoCAP system (Thermo Fisher Scientific, Uppsala, Sweden). In all centres, total IgE 
and specific IgE were measured against Dermatophagoides pteronyssinus (house dust 
mite), timothy grass, and cat. IgE sensitization was defined as presence of IgE titres for a 
specific allergen ≥ 0.35 kU/L. Group-wise differences were studied regarding FENO in 
different combinations of specific IgE allergens. Group 1: non-sensitized (mite-, cat-, 
grass-negative); group 2: only sensitized to grass; group 3: only sensitized to perennial 
allergens (mite- and/or cat-positive); group 4: sensitized to both grass and perennial 
allergens (mite- and/or cat-positive). 
 
Measurements of exhaled NO 
NO measurements were performed in accordance with the recommendations of the 
American Thoracic Society(16), with the exception that they were performed as single 
measurements(17). Patients were instructed to avoid smoking, eating or drinking, and 
strenuous exercise in the hour before the measurement. FENO values were measured with 
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an electrochemical analyser (NIOX MINO; Aerocrine AB, Solna, Sweden) at an expiratory 
flow rate of 50 ml/s. This device detects exhaled NO values from 5 to 300 ppb. Values 
below 5 ppb (the lower limit of detection of the device) were recorded in 12 subjects and 
these received an arbitrary value of 3.5 ppb (5 divided by √2). No values above 300 ppb 
were recorded in our material. 
 
Statistical methods 
All analyses were performed using Stata 14.2 (StataCorp, College Station, TX, USA). The 
results are described as means, geometric mean values or back-transformed β-coefficient 
with 95% confidence intervals (CI). Logarithmic transformation was performed for 
variables with right skewed distribution (FENO, total IgE, current cigarettes per day, 
cigarette packs/10 years, and ex-pack/years).  
We have used known determinants of FENO from the literature as predictors of EFENO in 
our models: age, gender, height, BMI, smoking, asthma and allergy(18).  
All analyses were performed for men and women separately. Bivariate linear regression 
analyses were used to assess the cross-sectional associations between FENO level. Age was 
divided into age quartiles (39.7–48.3, 48.4–54.5, 54.6–60.2 and 60.3–67.6 years), height, 
weight, BMI group, smoking history, total IgE level, IgE sensitization to mite, cat, and 
grass group, and hay fever. Further, bivariate linear regression analysis were performed in 
relation to the number of cigarettes smoked daily and pack-years, in ex-smokers we 
analysed FENO levels in relation to smoked pack-years and time since stopped smoking.  
Multiple linear regression analyses were adjusted for age quartile, height, BMI group, 
smoking habits (three strata: never-, ex-, current smokers), IgE sensitization profile, hay 
fever, study centre, and self-reported asthma. Interaction analyses between sex and age 
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group, IgE allergen group (mite, cat and grass), smoking group, current cigarettes, time 
since stopped smoking, and ex-pack-years were performed on FENO as outcome.  
 
These multiple linear regression analyses were also tested for consistency when using a 
mixed linear model where grouping was done according to study centre(19). 
 
The regression coefficient for the predictor variable of interest (logFENO) was back-
transformed when the independent variable was normally distributed, by taking the antilog 
of the estimated transformed FENO value. Coefficients should be interpreted as the % 
change of FENO when the independent variables change one unit or in relation to the 
reference group (for example smokers vs. never-smokers). When both the dependent and 
independent variables were log-transformed, no reverse transformation was performed (1% 
increase in the independent variable gave the coefficient percent increase of the dependent 
variables).  
 
A p value of < 0.05 was considered statistically significant. 
 
Ethics 
Informed consent was obtained from all participants prior to inclusion in ECRHS III. Each 
study centre obtained approval for the study from their regional committee of medical 





In total, 1,912 (49.3%) of the 3,881 participants were women. The mean age was 54.4 
years for men and 53.9 years for women. Exhaled NO levels were higher in men than in 
women: (geometric mean) 18.2 (95% confidence interval (CI):17.7 to 18.6) vs. 15.0 (14.7 
to 15.4) ppb, p<0.001. Baseline characteristics by sex are given in Table 1. 
 
Exhaled NO in relation to anthropometric characteristics. 
Men had a 21.3% higher level of FENO compared with women. Age was positively 
associated with FENO level. Men in the highest age quartile (60.3–67.6 years) had 19.2 
ppb (95% CI: 18.3, 20.2) higher FENO than subjects in the lowest age quartile (39.7–48.3 
years) p=0.02. Women in the two highest age quartiles (54.6–60.2 and 60.3–67.6 years) 
had 15.4 ppb (14.7, 16.2), p=0.03 and 16.4 ppb (15.6, 17.1), p=<0.001 higher FENO, 
compared with the lowest age quartile. No crude associations were observed between 
FENO and height, weight, or BMI (Supplementary table 1). 
 
Exhaled NO levels and smoking  
Men who never smoked had significantly higher levels of FENO (geometric mean [95% 
CI]) (20.5 ppb (19.8, 21.3)) than ex-smokers (19.3 ppb (18.6, 20.0), p=0.02) and current 
smokers (12.6 ppb (11.9, 13.3), p<0.001). Women who never smoked had significant 
higher levels of FENO (geometric mean [95% CI]) (16.3 ppb (15.8, 16.8)) than current 
smokers (10.9 ppb (10.4, 11.5), p<0.001) while no difference between never- and ex-
smokers could be found (p=0.19, Figure 2 and Supplemental Table 1). No significant 





For men that were ex-smokers there was a positive association between FENO and the time 
since they had stopped smoking (coefficient by 10 years: 1.05 (95% CI: 1.02, 1.08)), no 
significant association was seen in women. Further, no association was found between 
smoking history (pack-year) and FENO level in ex-smoking men and women. Among 
current smokers, a significant negative association was found between FENO level and 
number of cigarettes per day and pack-years (both p=0.001) in both men and women 
(Table 2). 
 
Exhaled NO and the relation to IgE sensitization, mite, cat, and grass exposure 
Total IgE was associated with higher levels of FENO in women (p=0.02), but not in men 
(p=0.91). Men and women sensitized to mite, cat or grass had higher levels of FENO 
compared with non-sensitized subjects (p<0.001, separate analyses for one allergen at a 
time).  
 
When studying the allergens in different combinations, men sensitized to grass had 13% 
(95% CI; 3, 25%) higher FENO levels than non-sensitized subjects; for perennial allergens 
(cat and mite) the levels were 11% (95% CI; 2, 20%) higher, and for grass and perennial 
allergens 33% (95% CI; 19, 48%) higher. Women sensitized to grass had 11% (95% CI; 2, 
22%) higher FENO levels than those non-sensitized, for perennial allergens (cat and mite) 
the levels were 15% (95% CI; 5, 26%) higher, and for grass and perennial allergens 35% 







Multivariate model of determinants of exhaled NO  
When we stratified by sex and age groups, the oldest men (60.3–67.6 years) had 9% (95% 
CI; 1-16%, p=0.02) higher FENO values than men in the lowest age quartile (39.7–48.3 
years). Women in the two highest age quartiles (54.5–60.2 and 60.3–67.7 years) had 8% 
(95% CI; 1-14%, p=0.02) and 13% (95% CI; 6-21%, p<0.001) higher FENO values, 
respectively, than those in the lowest age quartile (39.7–48.3 years). Height was related to 
8% (95% CI; 5-12%, p<0.001) higher FENO level in men and 5% (95% CI; 1-9%, 
p=0.008) higher FENO levels in women (Fig. 4 and Supplemental Table 2). BMI was not 
significantly related to FENO levels (data not shown). Men who smoked had 37% (95% CI; 
32-41%) lower FENO levels and women 30% (95% CI; 25-34%) lower compared with 
never-smokers (p<0.001 for both). Among ex-smokers, men had 5% lower FENO levels 
compared with never-smokers (p=0.02). No significant associations were seen between 
FENO and women who were ex-smokers compares with never-smokers. 
 
Men and women sensitized to both grass and perennial allergens had higher FENO levels 
compared with non-sensitized subjects (26% 95% (CI; 14-39%) and 29% (95% CI; 16-
43%), p<0.001 for both). Only men showed significant effects of grass sensitization on 
FENO (p=0.02 in men, p=0.13 in women). Women who were sensitized to perennial 
allergens (mite and/or cat) had higher levels of FENO than non-sensitized women 
(p=0.003). No significant association was seen among men (p=0.09) (Fig. 4 and 
Supplemental Table 2). No significant association was seen between hay fever and FENO 
levels (data not shown). These results were consistent, both regarding significance and size 




The only significant interaction between sex and other predictors (age group, IgE allergen 
group (mite, cat and grass), smoking group, current cigarettes, time since stopped smoking, 
and ex-pack-years) was between sex and current smoking (p<0.05), both in a multiple 
linear regression model or mixed model (Supplementary Table 3). 
 
Discussion 
We have found that FENO levels were about 21% higher in males than females in this large 
European multicentre study of healthy, middle-aged subjects. Similar determinants of 
FENO were found to be associated with higher FENO levels in both males and females with 
increased height and IgE sensitization. Current smoking was found to be associated with 
lower FENO levels and the size of this effect was larger in men than women. Higher age 
related to higher FENO levels, and this effect was seen at a lower age in women than men. 
Previous smoking was related to a small, but significant decrease of FENO levels in men. 
 
In our study, FENO levels were 21% higher in men than women (18.2 vs15.0 ppb). Several 
previous studies have also reported an association between increased FENO levels and 
male sex(20-23). Kim et al.(22) reported, based on data from 166 healthy Korean adults 
(aged 20–68 years), that men had 27% higher FENO levels than women (35.7 vs 26.0 ppb). 
Taylor et al.(23) studied 895 healthy adults at age 32 years and found that men had 
approximately 25% higher FENO levels than women (15.5 vs 11.6 ppb). A similar size of 
the sex difference has also been reported in asthmatic subjects(21, 24) – for example, Al-
shamkhi et al.(21) reported that in 557 subjects with asthma from the Swedish GA2LEN 
study, men had 32% higher FENO levels than women (24.0 vs 16.4 ppb). However, not all  
studies have been able to detect sex differences of FENO(25, 26). Olin et al.(25) studied 
2,200 randomly selected healthy adults, aged 25 to 75 years, and reported that sex was not 
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independently associated with FENO. In a recent study by Högman et al.(26) on 433 
healthy subjects, age 7–78 years, a significant sex effect on FENO levels could be reported 
only for the middle age group, 20–49 years. The mechanism of how sex affects FENO is 
not fully understood, but a few hypotheses are worth mentioning. Greater height(27) could 
explain larger lung and airway size, leading to larger surface of the airway mucosa, larger 
airway calibre, and increased NO release(20, 28). However, this could only partly explain 
our differences, as male sex was still associated with increased FENO level after 
adjustment for height. Other potential mechanisms might be genetic differences(29) and 
effects of oestrogen(30, 31).  
 
Our study showed a significantly increased level of FENO after age 55 in women and age 
60 in men. Jacinto et al.(11) reported an increase in FENO level in the age group 14–16 
years, depending on sex, based on data from the National Health and Nutrition 
Examination Survey (NHANES). Beyond this age, FENO plateaus and shows stable values 
until age 45 years in women and age 59 years in men, when it starts to increase. There 
were some differences between our study and the study of Jacinto et al. regarding studied 
population, as Jacinto et al. excluded subjects with hay fever, previous/current smoking, 
and suspicion of inflammatory diseases. These changes in FENO seem related to somatic 
growth in childhood, which ends in the upper teens. The increase from middle age and up 
may be primarily related to structural changes in the lungs, for example loss of alveolar 
elastic recoil and alveolar surface area(32) and reduced alveolar capillary diffusion of 
NO(26, 33). This process probably starts earlier in women than men and to some extent 
explains the present findings and the findings of Jacinto et al. However, a recent study on 
303 healthy, non-smoking seniors, aged over 65 years (with a mean age of 85 years), found 
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no difference in FENO values between males and females(34), so a cohort study covering 
all ages would be of interest to fully understand the relation of FENO to age and sex. 
 
In the present study, current and ex-smokers showed lower FENO levels compared with 
never-smokers. This result is in accordance with a study of Xu et al. on 11,160 subjects 
from NHANES; they showed that active smoking, measured by self-report, among healthy 
and asthmatic subjects, was associated with 37% and 45% lower FENO levels, 
respectively(35). In the present study, there was a significant interaction between sex and 
current smoking. However, this is likely to be due to the fact that men smoked more, as no 
interaction with sex on FENO levels was found in relation to number of smoked cigarettes. 
This argues against the idea that women might be more sensitive to smoking in terms of 
FENO reduction. 
 
Further, there was a relation between previous smoking and FENO in men in form of a 5% 
reduction in FENO levels. Other authors diverge on this matter, reporting a decrease(36), 
no effect(25, 37), or an increase of FENO levels(38). We also found that in men there was 
an association with time since they stopped smoking, suggesting that the decrease might be 
seen among all men who stopped smoking recently. However, this effect was not found in 
women. Several mechanisms on the link of current smoking with decreased FENO have 
been proposed: down-regulation of enzymatic NO formation in the bronchial compartment, 
as well as in the oropharyngeal compartment(39). Interferon gamma, which is present in 
normal airways, seem to be down-regulated in smokers, which leads to a decreased 
expression of iNOS in the human respiratory epithelium(39); another potential mechanism 
is that smoke contains high levels of NO, which has been found to have an inhibitory 




Allergic sensitization was associated with higher levels of FENO, especially when subjects 
were sensitized to both grass and mite and/or cat allergens. IgE sensitization has in other 
studies been shown to be related to higher FENO levels(14, 38) and a degree of IgE 
sensitization has been reported to relate to FENO levels, either when assessed as titres of 
IgE(14) or number of sensitizations/types of allergens. In a study by Yau et al. on 1,321 
healthy children, significant positive associations were found between FENO and specific 
allergens, and between FENO and the number of sensitizations. However, Silvestri et al. 
studied 112 children with stable, mild intermittent asthma and no differences were seen 
between FENO levels and mono- and poly-sensitized subjects(41).  
 
We found no significant association between BMI and FENO levels in the multivariate 
model. These results indicate that BMI has no effect on FENO levels, and that FENO is 
affected to a greater extent by confounders such as sex, age, and height. Our results are in 
accordance with a study by Kim et al., a cross-sectional study on 117 healthy subjects, 
aged 20–68 years, which could not find any significant association between BMI and 
FENO(42). Similar results were also seen in a study on healthy children(43). However, 
some studies have shown contradictory results. Studies by De Winter-de Groot et al.(44), 
on 24 healthy non-smoking subjects, and by Kazaks et al.(45), on 25 healthy subjects, 
reported a significant positive association between BMI and FENO. 
 
The main strength of the current report is the use of a large, multicentre, general population 
sample with high quality and standardized measurements of exhaled NO, using the same 
type of device in all centres. Nevertheless, some limitations must be taken into 
consideration. ECRHS III does not include measures of bronchial responsiveness. We 
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excluded subjects with self-reported asthma and/or asthma symptoms in the 12 months 
preceding the questionnaire. Thus, it is possible that subjects with no or minimal symptoms 
in the most recent 12 months might be enrolled as healthy subjects. However, subjects 
receiving medication were excluded, which would argue against subjects with asthma 
having been enrolled as healthy subjects. Also, having subjects from different centres and 
geographical areas is a strength indicating that these findings could be valid in the general 
population. The present population is recruited from the random sample of ECRHS. 
However due the long-term follow-up time and this is a second follow up, so selection bias 
can´t be ruled out.  
 
Our data confirm a difference in FENO levels between men and women. Present algorithm 
for clinical interpretation FENO do not take sex in to account. FENO started increasing at 
lower age in women than in men, suggesting that interpretation of FENO levels in adults 
aged over 50 years should take into account both age and sex. Similar determinants and 
effect sizes of different confounders such as current smoking and IgE sensitization could 
also be found for both men and women. The absolute effect size in this study was not very 




ATS  American Thoracic Society 
BMI  Body mass index 
ECRHS  European Community Respiratory Health Survey 
FENO  Fractional exhaled nitric oxide 
IgE  Immunoglobulin E 
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Table 1. Baseline characteristics of participants divided by whole sample, men and women  
Variable Men 
(n = 1,969) 
Women 
(n = 1,912) 
FENO (ppb)* (geometric), 95% CI 18.2 (17.7, 18.6) 15.0 (14.7, 15.4) 
Age (years) 54.4 (±7.1) 53.9 (±7.0) 
Age (quartile), n (%) 
Q1: 39.7–48.3 years  
Q2: 48.4–54.5 years 
Q3: 54.6–60.2 years 











Height (m) 1.77 (±0.07) 1.64 (±0.07) 
Weight (kg) 85.7 (±14.6) 70.9 (±14.4) 
BMI (kg/m2), n (%) 
< 18.5 
>18.5 to 25 
>25 to 30 














Total IgE (kU/L) (geometric), 95% CI 28.3 (26.4, 30.4) 20.6 (19.1, 22.2) 
IgE sensitized to different allergen, n (%): 
Non-sensitized  
Sensitized only to grass pollen 
Sensitized only to perennial allergens  











Hay fever, yes, n (%) 478 (24.3) 536 (28.1) 
Smoking:  













(geometric mean, 95% CI) 
Number cig/day  
Pack-years 
11.0 (10.0, 12.1) 
25.7 (23.6, 27.9) 
8.2 (7.4, 9.1) 
18.0 (16.4, 19.4) 
Ex-smokers (±SD) 
(geometric mean, 95% CI) 
Time since stopped 
smoking (year) 
Pack-years  
17.7 (±11.6)  
 
8.8 (8.0, 9.8) 
18.4 (±11.1) 
 
6.9 (6.3, 7.6) 
Values: n [%] and mean [±SD]. Perennial allergens (mite- and/or cat-positive). Abbreviations: BMI: body 







Table 2. Bivariate linear regression analysis, (β-coefficient, 95% CI) between FENO and ex-smokers time since stopped smoking/ex-packs per year  






FENO and time since stopped smoking in ex-smokers has been back-transformed. Example: β-coeff. = 1.05 means that subjects  
who have quit smoking have 5% higher FENO levels per 10 years. When both dependent and independent variable were  
log transform, the β-coefficient should be interpreted as the % change of FENO when the independent variable changes 1 %  
(e.g., 1% increase in cigarettes/day leads to 0.16 % decreased FENO levels). Abbreviations: FENO: fractional exhaled  
nitric oxide, CI: confidence interval.  
 
logFENO Men Women 
 β-coefficient (95% CI) p value β-coefficient (95% CI) p value 
Ex-smokers:  Time since stopped smoking/10 years 1.05 (1.02, 1.08) 0.004 1.02 (0.99, 1.05) 0.33 
                        log Ex packs/year  0.01 (-0.02, 0.04) 0.44 -0.004 (-0.04, 0.03) 0.80 
Smokers:       log No. cigarettes/day  -0.16 (-0.23, -0.11) < 0.001 -0.12 (-0.18, -0.06) < 0.001 
                       log Current packs/year  -0.21 (-0.28, -0.15) < 0.001 -0.11 (-0.17, -0.04) 0.001 
